For how long should antifungals be continued in patients with urine Candida auris positive after negative culture reports?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 3, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Duration of Antifungal Therapy for Urine Candida auris After Negative Culture Reports

Antifungal therapy for urinary Candida auris should be continued for 14 days after documented clearance of the organism from urine cultures and resolution of symptoms attributable to the infection.

Treatment Approach for Candida auris in Urine

Initial Treatment Selection

  • Echinocandins (caspofungin, anidulafungin, or micafungin) are the preferred first-line agents for most patients with C. auris isolated in urine due to the organism's frequent resistance to fluconazole 1, 2
  • Liposomal amphotericin B (3-5 mg/kg daily) is an effective alternative, particularly in cases where echinocandins cannot be used 1, 3
  • Conventional amphotericin B deoxycholate (0.7-1.0 mg/kg/day) can be considered in settings where liposomal formulations are unavailable 3

Duration of Therapy

  • For candiduria without evidence of disseminated infection, treatment should continue for 14 days after the first negative urine culture and resolution of symptoms 3
  • For patients with persistent fungemia or metastatic complications, longer treatment courses may be necessary 3
  • Premature discontinuation of antifungal therapy may lead to recurrent infection, particularly in immunocompromised patients 3

Special Considerations for C. auris

  • C. auris is characterized by multidrug resistance, difficult eradication, and high potential for healthcare-associated transmission 1, 4
  • Even after treatment, patients may remain colonized for long periods, requiring ongoing infection control measures 4
  • More aggressive and prolonged treatment approaches may be necessary compared to other Candida species due to C. auris' resistance profile 1, 2

Monitoring During and After Treatment

Follow-up Cultures

  • Repeat urine cultures should be performed to document clearance of the organism 3
  • Persistent positive cultures may indicate inadequate source control, resistance development, or presence of foreign bodies (catheters) 3, 1

Assessment for Dissemination

  • In patients with persistent C. auris in urine, evaluation for systemic spread should be considered, including blood cultures 5, 6
  • Imaging of the genitourinary tract may be warranted in cases of persistent infection to rule out abscess or obstruction 3

Infection Control Considerations

  • Remove urinary catheters whenever possible, as catheterization is a common risk factor for C. auris infection 3, 2
  • Implement strict contact precautions and environmental cleaning to prevent transmission to other patients 4
  • Continue infection control measures even after negative cultures due to potential for prolonged colonization 4

Common Pitfalls and Caveats

  • Misidentification of C. auris is common with conventional laboratory techniques, potentially leading to inappropriate treatment 1, 2
  • Premature discontinuation of therapy before complete eradication may lead to recurrence and development of resistance 3, 4
  • Failure to remove urinary catheters when possible can lead to persistent infection despite appropriate antifungal therapy 3
  • Underestimating the transmission potential of C. auris can lead to healthcare-associated outbreaks 4

Treatment Outcomes

  • Clinical success rates of approximately 83% have been reported for patients treated for C. auris infections 6
  • Mortality rates remain significant (approximately 17% within 30 days) highlighting the importance of prompt and appropriate therapy 6
  • Echinocandins have shown favorable outcomes in most patients with C. auris infections 6, 2

References

Research

Candida auris Urinary Tract Infections and Possible Treatment.

Antibiotics (Basel, Switzerland), 2020

Research

A rare fungus on the rise: Candida auris.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2018

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

An Overview on Candida auris in Healthcare Settings.

Journal of fungi (Basel, Switzerland), 2023

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.